Ketamine can produce hallucinations, but it isn’t a classical hallucinogen. It belongs to a separate drug class called dissociative anesthetics, which work through an entirely different brain mechanism than psychedelics like psilocybin or LSD. The confusion is understandable: at certain doses, ketamine causes visual distortions, out-of-body experiences, and altered perception of time and space, all of which overlap with what people associate with hallucinogens.
How Ketamine Differs From Classical Hallucinogens
Classical hallucinogens like psilocybin and LSD work primarily by activating serotonin receptors (specifically the 5-HT2A type) on the brain’s pyramidal neurons. This triggers a cascade of glutamate release that alters perception, emotion, and thought patterns. The experience tends to involve vivid visual imagery, synesthesia, emotional intensity, and a sense of expanded consciousness while still feeling anchored in the physical world.
Ketamine does something fundamentally different. It blocks NMDA receptors, which are part of the brain’s glutamate signaling system. Instead of activating a receptor, ketamine physically lodges inside the ion channel and prevents signals from passing through. This blockade hits inhibitory brain cells first, which paradoxically leads to a surge of glutamate activity elsewhere. The result is dissociation: a feeling of detachment from your body and surroundings rather than the sensory amplification that defines a classical psychedelic trip.
Both drug types ultimately increase glutamate activity in the brain’s outer layers, but they arrive there through completely different doors. That shared downstream effect helps explain why their experiences can overlap at times, even though the core pharmacology is distinct.
What Ketamine Actually Feels Like
The effects of ketamine depend heavily on dose. At low doses, people typically feel a mild floatiness, slight detachment from their body, and altered time perception. Colors may seem brighter. Sounds may feel distant or distorted. Many people describe a sense of “melting into the surroundings,” which was cited as one of the most appealing effects by two-thirds of recreational users in one study published in Drug and Alcohol Dependence.
At moderate doses, the dissociation deepens. Visual hallucinations can occur, along with dream-like states and difficulty distinguishing what’s real from what isn’t. This is the range where ketamine most closely mimics a hallucinogenic experience, though the quality of the hallucinations tends to feel more internal and dreamlike rather than the vivid, eyes-open distortions typical of psilocybin.
At high doses (roughly 150 mg or more in a recreational context), ketamine can produce what’s known as a “K-hole,” an experience of intense detachment where perceptions feel buried deep within consciousness and the outside world seems impossibly far away. People describe out-of-body experiences, complete ego dissolution, and a sense of traveling through abstract mental landscapes. The K-hole is often compared to a near-death experience more than a psychedelic trip. On the less appealing side, about half of users report memory loss and decreased sociability as notable downsides.
Medical Classification and Approved Uses
Pharmacologically, ketamine is classified as a noncompetitive NMDA receptor antagonist and dissociative anesthetic. It was developed in the 1960s as a surgical anesthetic, and that remains its primary medical identity. At anesthetic doses given by injection into muscle, it produces 12 to 30 minutes of surgical anesthesia with onset in 3 to 5 minutes. Intravenously, an average anesthetic dose produces about 5 to 10 minutes of dissociative anesthesia.
The more recent medical interest in ketamine centers on much lower doses. Sub-anesthetic infusions, typically 0.3 to 0.5 mg/kg delivered intravenously, are used for acute pain management. A related compound called esketamine (a mirror-image version of the ketamine molecule) is FDA-approved as a nasal spray for treatment-resistant depression in adults, as well as for depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. It’s worth noting that esketamine’s approval for suicidal ideation relates to treating the underlying depressive symptoms, not preventing suicide directly.
Even at these therapeutic doses, patients commonly experience some degree of dissociation, which is why esketamine treatments are administered in a clinical setting with monitoring afterward.
How Dose Shapes the Experience
The gap between a therapeutic dose and a hallucinatory one is significant. Sub-anesthetic doses used for pain relief (0.1 to 0.4 mg/kg IV) may cause mild perceptual changes: things feel slightly unreal, the body feels lighter, and the mind drifts. These effects are noticeable but not overwhelming for most people.
Clinical guidelines for acute pain recommend that bolus doses stay below 0.35 mg/kg and infusions generally remain under 1 mg/kg per hour in settings without intensive monitoring. At these levels, you’re unlikely to experience full-blown hallucinations, though some perceptual weirdness is common. The hallucinatory and deeply dissociative effects that blur the line with classical psychedelics tend to emerge at doses several times higher than what’s used therapeutically.
Risks of Regular Use
One of the most well-documented risks of frequent ketamine use is bladder damage. Ketamine-induced cystitis was first reported in 2007 among daily users and causes urinary urgency, painful urination, frequent urination, and blood in the urine. Over 25% of people who use ketamine recreationally develop urinary symptoms, and regular use increases the risk of cystitis three- to four-fold compared to non-users. Among those with severe symptoms, nearly 90% showed thickened bladder walls on imaging, and 44% had kidney swelling from backed-up urine. In chronic users who underwent bladder biopsy, 75% showed damage to the bladder lining.
The severity tracks closely with how much and how often someone uses ketamine. Infrequent users report cystitis-like symptoms at a rate of about 7%, while frequent users report them at roughly 20%. In advanced cases, the damage can progress to narrowing of the ureters and kidney failure.
Beyond the bladder, regular ketamine use can impair attention and memory, and carries a risk of psychological dependence. Acute use alters the sense of time, visual and auditory perception, and the ability to form new memories. These cognitive effects can persist in heavy, long-term users even between doses.
So Is It a Hallucinogen or Not?
The most accurate answer is that ketamine is a dissociative anesthetic that can produce hallucinogenic effects, particularly at moderate to high doses. It shares a family tree with PCP rather than with LSD or psilocybin. The Drug Enforcement Administration classifies it as a Schedule III controlled substance (classical hallucinogens like psilocybin are Schedule I), reflecting its recognized medical uses and different risk profile.
If you encounter ketamine grouped under “hallucinogens” in casual writing, that’s not entirely wrong since it does cause hallucinations. But in pharmacological terms, calling ketamine a hallucinogen is like calling a dolphin a fish because it swims. The mechanism, the quality of the experience, and the medical applications are distinct enough that most scientists and clinicians place it in its own category.